Novavax agreed to refund up to $400 million to Gavi, the international organization that purchased COVID-19 shots as part of a global vaccination program but found itself with vaccines that were no longer needed. Gavi found itself in a precarious position due to events surrounding the initial efforts to create the global vaccination program. (STAT News)

AbbVie announced a $64 million collaboration with Tentarix Biotherapeutics to use its Tentacles platform for developing conditionally active, multi-specific biologic candidates in oncology and immunology. The company said that it plans to expand its oncology and immunology portfolio with the partnership. (Nasdaq)

Daytime talk show legend Wendy Williams was diagnosed with dementia and apahasia. Williams’ long-running daytime talk show was canceled in 2022 after a medical leave during a battle with the autoimmune disorder Graves’ disease. (USA Today)

Amylyx Therapeutics said the outcome of a Phase 3 study of its treatment for ALS could come before the start of the second quarter, which is earlier than previously expected. The news, coupled with a quarterly revenue beat, sent the company’s stock upward on Thursday. (Seeking Alpha)

India pharma companies have begun to develop versions of Wegovy in an effort to get in on the GLP-1 weight loss drug windfall. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy’s, and Lupin all said they have started work on Wegovy versions. (Reuters)

Click here to see yesterday’s Five things for pharma marketers to know.